RecruitingNCT05022459
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
Studying Moderate hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Wayne State University
- Principal Investigator
- Meera Chitlur, MDWayne State University
- Intervention
- Emicizumab(drug)
- Enrollment
- 72 enrolled
- Eligibility
- 6-19 years · All sexes
- Timeline
- 2023 – 2029
Study locations (9)
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Stanford University, Palo Alto, California, United States
- Rady Children's Hospital, San Diego, California, United States
- Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
- Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Children's Hospital of Michigan, Detroit, Michigan, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Oklahoma Center for Bleeding and Clotting Disorders, Oklahoma City, Oklahoma, United States
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05022459 on ClinicalTrials.govOther trials for Moderate hemophilia A
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT04676048ASC618 Gene Therapy in Hemophilia A PatientsASC Therapeutics
- ACTIVE NOT RECRUITINGPHASE4NCT05181618A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab ProphylaxisHoffmann-La Roche